TransThera Sciences Issues 5.09 Million H Shares in April Placement, Expanding Total Share Capital to 404.08 Million

Bulletin Express05-06

TransThera Sciences (Nanjing), Inc. filed its Monthly Return for the period ended 30 April 2026, highlighting a placement-driven expansion of its equity base.

The company allotted 5.09 million new H shares on 21 April 2026 at HKD 57.03 per share, an issuance previously approved on 4 August 2025. The transaction lifted the number of issued H shares to 308.85 million, up from 303.77 million a month earlier. Unlisted ordinary shares remained unchanged at 95.23 million.

Following the placement, authorised and issued share capital stood at 404.08 million shares with a par value of RMB 1 each. No treasury shares were outstanding, and no share options, warrants or convertible instruments were exercised during the month.

The issuer confirmed compliance with the Main Board’s minimum public-float requirement of 25 percent for its H shares. All regulatory filings and corporate formalities associated with the share issuance were completed, according to statements signed by the Joint Company Secretary.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141413135?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 16:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141413135","market":"us","top_or_hot":-1,"title":"TransThera Sciences Issues 5.09 Million H Shares in April Placement, Expanding Total Share Capital to 404.08 Million","media":"Bulletin Express","content":"<p>TransThera Sciences (Nanjing), Inc. filed its Monthly Return for the period ended 30 April 2026, highlighting a placement-driven expansion of its equity base.</p>\n<p>The company allotted 5.09 million new H shares on 21 April 2026 at HKD 57.03 per share, an issuance previously approved on 4 August 2025. The transaction lifted the number of issued H shares to 308.85 million, up from 303.77 million a month earlier. Unlisted ordinary shares remained unchanged at 95.23 million.</p>\n<p>Following the placement, authorised and issued share capital stood at 404.08 million shares with a par value of RMB 1 each. No treasury shares were outstanding, and no share options, warrants or convertible instruments were exercised during the month.</p>\n<p>The issuer confirmed compliance with the Main Board’s minimum public-float requirement of 25 percent for its H shares. All regulatory filings and corporate formalities associated with the share issuance were completed, according to statements signed by the Joint Company Secretary.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransThera Sciences Issues 5.09 Million H Shares in April Placement, Expanding Total Share Capital to 404.08 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransThera Sciences Issues 5.09 Million H Shares in April Placement, Expanding Total Share Capital to 404.08 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-06 16:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TransThera Sciences (Nanjing), Inc. filed its Monthly Return for the period ended 30 April 2026, highlighting a placement-driven expansion of its equity base.</p>\n<p>The company allotted 5.09 million new H shares on 21 April 2026 at HKD 57.03 per share, an issuance previously approved on 4 August 2025. The transaction lifted the number of issued H shares to 308.85 million, up from 303.77 million a month earlier. Unlisted ordinary shares remained unchanged at 95.23 million.</p>\n<p>Following the placement, authorised and issued share capital stood at 404.08 million shares with a par value of RMB 1 each. No treasury shares were outstanding, and no share options, warrants or convertible instruments were exercised during the month.</p>\n<p>The issuer confirmed compliance with the Main Board’s minimum public-float requirement of 25 percent for its H shares. All regulatory filings and corporate formalities associated with the share issuance were completed, according to statements signed by the Joint Company Secretary.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02617","symbol_name":"药捷安康-B","start_time":0,"source_url":"","article_id":"1141413135","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141413135","pubTimestamp":1778054607,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"TransThera Sciences (Nanjing), Inc. filed its Monthly Return for the period ended 30 April 2026, highlighting a placement-driven expansion of its equity base. The company allotted 5.09 million new H...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02617":"药捷安康-B"},"translate_title":"Tranthera Sciences 4月配售发行509万股H股总股本扩大至4.0408亿股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1},"content_text":"TransThera Sciences (Nanjing), Inc. filed its Monthly Return for the period ended 30 April 2026, highlighting a placement-driven expansion of its equity base.\nThe company allotted 5.09 million new H shares on 21 April 2026 at HKD 57.03 per share, an issuance previously approved on 4 August 2025. The transaction lifted the number of issued H shares to 308.85 million, up from 303.77 million a month earlier. Unlisted ordinary shares remained unchanged at 95.23 million.\nFollowing the placement, authorised and issued share capital stood at 404.08 million shares with a par value of RMB 1 each. No treasury shares were outstanding, and no share options, warrants or convertible instruments were exercised during the month.\nThe issuer confirmed compliance with the Main Board’s minimum public-float requirement of 25 percent for its H shares. All regulatory filings and corporate formalities associated with the share issuance were completed, according to statements signed by the Joint Company Secretary.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141413135","isCrawlerRequest":true}